Significant improvement in Renal Cell Carcinoma (RCC) treatment was witnessed for the last 5-10 years, which prolonged the survival of RCC patients.
For example, the prognosis of patients with metastatic disease used to ne less than 1 year, but now increased 4 years.
It is due to new molecular targeted therapy and immunotherapy.